Study Status: COMPLETED
Recruit Status: COMPLETED
Study Type: INTERVENTIONAL
Official Title: A Phase 2 Trial of N-Acetylcysteine in Biliary Atresia After Kasai Portoenterostomy
Brief Summary:
Biliary atresia (BA) is a devastating liver disease of infancy, characterized by bile duct obstruction leading to liver fibrosis, cirrhosis, and eventual need for transplantation in most cases.
BA is treated with Kasai portoenterostomy (KP).
KPs can achieve bile drainage and improve outcomes.
However, even with standard evidence of "good bile flow," bile flow rarely normalizes completely and liver disease continues to progress.
In this study, the investigators test whether intravenous N-acetylcysteine (NAC) can improve bile flow after KP.
The rationale is that NAC leads to synthesis of glutathione, which is a powerful stimulator of bile flow.
The primary objective is to determine whether NAC normalizes total serum bile acid (TSBA) concentrations within 24 weeks of KP.
Achieving normal TSBAs is uncommon with current standard-of-care, and is predicted to be associated with better long-term outcomes.
The secondary objectives are to describe how other parameters commonly followed in BA change with NAC therapy, as well as report adverse events occurring with therapy and in the first two years of life.
This study follows the "minimax" Phase 2 clinical trial design.